64Cu-based Radiopharmaceuticals in Molecular Imaging

Technol Cancer Res Treat. 2019 Jan 1:18:1533033819830758. doi: 10.1177/1533033819830758.

Abstract

Copper-64 (T1/2 = 12.7 hours; β+: 19%, β-: 38%) has a unique decay profile and can be used for positron emission tomography imaging and radionuclide therapy. The well-established coordination chemistry of copper allows for its reaction with different types of chelator systems. It can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. Two potential ways to produce copper-64 radioisotopes concern the use of the cyclotron or the reactor. This review summarized several commonly used biomarkers of copper-64 radionuclide.

Keywords: PET/CT; copper-64.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Copper Radioisotopes / metabolism*
  • Humans
  • Molecular Imaging / methods*
  • Neoplasms / diagnosis*
  • Neoplasms / metabolism
  • Radiopharmaceuticals / metabolism*

Substances

  • Copper Radioisotopes
  • Copper-64
  • Radiopharmaceuticals